WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction

Lianne Robinson, Anushka V. Goonawardena, Roger G. Pertwee, Robert Hampson, Bettina Platt, Gernot Riedel

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Cannabinoids acting on CB1 receptors induce learning and memory impairments. However, the identification of novel non-CB1 receptors which are insensitive to the psychoactive ingredient of marijuana, Delta(9)-tetrahydrocannabinol (Delta(9)-THC) but sensitive to synthetic cannabinoids such as WIN55,212-2 (WIN2) or endocannabinoids like anandamide lead us to question whether WIN-2 induced learning and memory deficits are indeed mediated by CB1 receptor activation. Given the relative paucity of receptor subtype specific antagonists, a way forward would be to determine the transmitter systems, which are modulated by the respective cannabinoids. This study set out to evaluate this proposition by determination of the effects of WIN-2 on acquisition of spatial reference memory using the water maze in rats. Particular weight was given to performance in trial 1 of each daily session as an index of between-session long-term memory, and in trial 4 as an index of within-session short-term memory. Intraperitoneal (i.p.) administration of WIN-2 (1 mg/kg and 3 mg/kg) prior to training impaired long-term, but not short-term memory. This deficit was not reversed by the CB1 antagonists/inverse agonists Rimonabant (3 mg/kg i.p.) and AM281 (0.5 mg/kg i.p.), but recovered in the presence of the cholinesterase inhibitor rivastigmine (1 mg/kg). Reversal by rivastigmine was specific to WIN-2, as it failed to reverse MK801 (0.08 mg/kg) induced learning impairments.

Collectively, these data suggest that in this spatial reference memory task WIN-2 causes a reduction in cholinergic activation, possibly through a non-CB1-like mechanism, which affects long-term but not short-term spatial memory.

Original languageEnglish
Pages (from-to)584-592
Number of pages9
JournalBehavioural Brain Research
Volume208
Issue number2
Early online date14 Jan 2010
DOIs
Publication statusPublished - 2 Apr 2010

Keywords

  • cannabinoid
  • WIN-55,212-2
  • spatial learning
  • water maze
  • rivastigmine
  • cholinesterase inhibitor
  • rat
  • hippocampal acetylcholine-release
  • receptor antagonist SR141716A
  • induced memory impairment
  • rat prefrontal cortex
  • cannabinoid-receptor
  • SR 141716A
  • water-maze
  • working-memory
  • synaptic-transmission
  • mouse-brain

Cite this

WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction. / Robinson, Lianne; Goonawardena, Anushka V.; Pertwee, Roger G.; Hampson, Robert; Platt, Bettina; Riedel, Gernot.

In: Behavioural Brain Research, Vol. 208, No. 2, 02.04.2010, p. 584-592.

Research output: Contribution to journalArticle

@article{7b40ff011152478a8ea5638834a1eaca,
title = "WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction",
abstract = "Cannabinoids acting on CB1 receptors induce learning and memory impairments. However, the identification of novel non-CB1 receptors which are insensitive to the psychoactive ingredient of marijuana, Delta(9)-tetrahydrocannabinol (Delta(9)-THC) but sensitive to synthetic cannabinoids such as WIN55,212-2 (WIN2) or endocannabinoids like anandamide lead us to question whether WIN-2 induced learning and memory deficits are indeed mediated by CB1 receptor activation. Given the relative paucity of receptor subtype specific antagonists, a way forward would be to determine the transmitter systems, which are modulated by the respective cannabinoids. This study set out to evaluate this proposition by determination of the effects of WIN-2 on acquisition of spatial reference memory using the water maze in rats. Particular weight was given to performance in trial 1 of each daily session as an index of between-session long-term memory, and in trial 4 as an index of within-session short-term memory. Intraperitoneal (i.p.) administration of WIN-2 (1 mg/kg and 3 mg/kg) prior to training impaired long-term, but not short-term memory. This deficit was not reversed by the CB1 antagonists/inverse agonists Rimonabant (3 mg/kg i.p.) and AM281 (0.5 mg/kg i.p.), but recovered in the presence of the cholinesterase inhibitor rivastigmine (1 mg/kg). Reversal by rivastigmine was specific to WIN-2, as it failed to reverse MK801 (0.08 mg/kg) induced learning impairments.Collectively, these data suggest that in this spatial reference memory task WIN-2 causes a reduction in cholinergic activation, possibly through a non-CB1-like mechanism, which affects long-term but not short-term spatial memory.",
keywords = "cannabinoid, WIN-55,212-2, spatial learning, water maze, rivastigmine, cholinesterase inhibitor, rat, hippocampal acetylcholine-release, receptor antagonist SR141716A, induced memory impairment, rat prefrontal cortex, cannabinoid-receptor, SR 141716A, water-maze, working-memory, synaptic-transmission, mouse-brain",
author = "Lianne Robinson and Goonawardena, {Anushka V.} and Pertwee, {Roger G.} and Robert Hampson and Bettina Platt and Gernot Riedel",
year = "2010",
month = "4",
day = "2",
doi = "10.1016/j.bbr.2010.01.004",
language = "English",
volume = "208",
pages = "584--592",
journal = "Behavioural Brain Research",
issn = "0166-4328",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction

AU - Robinson, Lianne

AU - Goonawardena, Anushka V.

AU - Pertwee, Roger G.

AU - Hampson, Robert

AU - Platt, Bettina

AU - Riedel, Gernot

PY - 2010/4/2

Y1 - 2010/4/2

N2 - Cannabinoids acting on CB1 receptors induce learning and memory impairments. However, the identification of novel non-CB1 receptors which are insensitive to the psychoactive ingredient of marijuana, Delta(9)-tetrahydrocannabinol (Delta(9)-THC) but sensitive to synthetic cannabinoids such as WIN55,212-2 (WIN2) or endocannabinoids like anandamide lead us to question whether WIN-2 induced learning and memory deficits are indeed mediated by CB1 receptor activation. Given the relative paucity of receptor subtype specific antagonists, a way forward would be to determine the transmitter systems, which are modulated by the respective cannabinoids. This study set out to evaluate this proposition by determination of the effects of WIN-2 on acquisition of spatial reference memory using the water maze in rats. Particular weight was given to performance in trial 1 of each daily session as an index of between-session long-term memory, and in trial 4 as an index of within-session short-term memory. Intraperitoneal (i.p.) administration of WIN-2 (1 mg/kg and 3 mg/kg) prior to training impaired long-term, but not short-term memory. This deficit was not reversed by the CB1 antagonists/inverse agonists Rimonabant (3 mg/kg i.p.) and AM281 (0.5 mg/kg i.p.), but recovered in the presence of the cholinesterase inhibitor rivastigmine (1 mg/kg). Reversal by rivastigmine was specific to WIN-2, as it failed to reverse MK801 (0.08 mg/kg) induced learning impairments.Collectively, these data suggest that in this spatial reference memory task WIN-2 causes a reduction in cholinergic activation, possibly through a non-CB1-like mechanism, which affects long-term but not short-term spatial memory.

AB - Cannabinoids acting on CB1 receptors induce learning and memory impairments. However, the identification of novel non-CB1 receptors which are insensitive to the psychoactive ingredient of marijuana, Delta(9)-tetrahydrocannabinol (Delta(9)-THC) but sensitive to synthetic cannabinoids such as WIN55,212-2 (WIN2) or endocannabinoids like anandamide lead us to question whether WIN-2 induced learning and memory deficits are indeed mediated by CB1 receptor activation. Given the relative paucity of receptor subtype specific antagonists, a way forward would be to determine the transmitter systems, which are modulated by the respective cannabinoids. This study set out to evaluate this proposition by determination of the effects of WIN-2 on acquisition of spatial reference memory using the water maze in rats. Particular weight was given to performance in trial 1 of each daily session as an index of between-session long-term memory, and in trial 4 as an index of within-session short-term memory. Intraperitoneal (i.p.) administration of WIN-2 (1 mg/kg and 3 mg/kg) prior to training impaired long-term, but not short-term memory. This deficit was not reversed by the CB1 antagonists/inverse agonists Rimonabant (3 mg/kg i.p.) and AM281 (0.5 mg/kg i.p.), but recovered in the presence of the cholinesterase inhibitor rivastigmine (1 mg/kg). Reversal by rivastigmine was specific to WIN-2, as it failed to reverse MK801 (0.08 mg/kg) induced learning impairments.Collectively, these data suggest that in this spatial reference memory task WIN-2 causes a reduction in cholinergic activation, possibly through a non-CB1-like mechanism, which affects long-term but not short-term spatial memory.

KW - cannabinoid

KW - WIN-55,212-2

KW - spatial learning

KW - water maze

KW - rivastigmine

KW - cholinesterase inhibitor

KW - rat

KW - hippocampal acetylcholine-release

KW - receptor antagonist SR141716A

KW - induced memory impairment

KW - rat prefrontal cortex

KW - cannabinoid-receptor

KW - SR 141716A

KW - water-maze

KW - working-memory

KW - synaptic-transmission

KW - mouse-brain

U2 - 10.1016/j.bbr.2010.01.004

DO - 10.1016/j.bbr.2010.01.004

M3 - Article

VL - 208

SP - 584

EP - 592

JO - Behavioural Brain Research

JF - Behavioural Brain Research

SN - 0166-4328

IS - 2

ER -